SFA intakes have decreased in recent years, both in Ireland and across other European countries; however a large proportion of the population are still not meeting the SFA recommendation of <10% of total energy (TE). High SFA intakes have been associated with increased CVD and type-2 diabetes (T2D) risk, due to alterations in cholesterol homoeostasis and adipose tissue inflammation. PUFA, in particular EPA and DHA, have been associated with health benefits, including anti-inflammatory effects. It is well established that dietary fat composition plays an important role in biological processes. A recent review of evidence suggests that replacement of SFA with PUFA has potential to reduce risk of CVD and T2D. The public health and molecular impact of EPA and DHA have been well-characterised, while less is known of effects of α-linolenic acid (ALA). The current dietary guideline for ALA is 0·5% TE; however evidence from supplementation trials suggests that benefit is observed at levels greater than 2 g/d (0·6-1% TE). This review highlights the gap in the evidence base relating to effects of the replacement of SFA with ALA, identifying the need for randomised controlled trials to determine the optimal dose of ALA substitution to define the efficacy of dietary fat modification with ALA.
Keywords: ALA α-linolenic acid; HFD high-fat diet; HOMA-IR homoeostatic model assessment-insulin resistance; HR hazard ratio; LA linoleic acid; LC long chain; RCT randomised controlled trials; RR relative risk; SACN UK Scientific Advisory Committee on Nutrition; T2D type-2 diabetes; TC total cholesterol; TE total energy; TLR4 Toll-like receptor 4; Dietary fat intakes; PUFA; Public health strategy; SFA; α-Linolenic acid.